English | 繁體

Search in the results

UM

Browse/Search Results:  1-5 of 5 Help

Selected(0)Clear Items/Page:    Sort:
TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response Journal article
Zheng, Mengqi, Zhai, Yunjiao, Yu, Yanbo, Shen, Jing, Chu, Shuzheng, Focaccia, Enrico, Tian, Wenyu, Wang, Sui, Liu, Xuesong, Yuan, Xi, Wang, Yue, Li, Lixiang, Feng, Bingcheng, Li, Zhen, Guo, Xiaohuan, Qiu, Ju, Zhang, Cuijuan, Hou, Jiajie, Sun, Yiyuan, Yang, Xiaoyun, Zuo, Xiuli, Heikenwalder, Mathias, Li, Yanqing, Yuan, Detian, Li, Shiyang. TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response[J]. Cell Metabolism, 2024, 36(9), 2086-2103.
Authors:  Zheng, Mengqi;  Zhai, Yunjiao;  Yu, Yanbo;  Shen, Jing;  Chu, Shuzheng; et al.
Favorite | TC[WOS]:1 TC[Scopus]:3  IF:27.7/31.2 | Submit date：2024/08/05
Bile Acid  Detoxification  Infliximab  Tumor Necrosis Factor  Ulcerative Colitis  
Involvement of Bile Acid Metabolism and Gut Microbiota in the Amelioration of Experimental Metabolism-Associated Fatty Liver Disease by Nobiletin Journal article
Xu, Hongling, Yuan, Mingming, Niu, Kailin, Yang, Wei, Jiang, Maoyuan, Zhang, Lei, Zhou, Jing. Involvement of Bile Acid Metabolism and Gut Microbiota in the Amelioration of Experimental Metabolism-Associated Fatty Liver Disease by Nobiletin[J]. Molecules, 2024, 29(5), 976.
Authors:  Xu, Hongling;  Yuan, Mingming;  Niu, Kailin;  Yang, Wei;  Jiang, Maoyuan; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:4.2/4.6 | Submit date：2024/04/02
Bile Acid  Farnesoid x Receptor  Gut Microbiota  Metabolism-associated Fatty Liver Disease  Nobiletin  
Kaempferol acts on bile acid signaling and gut microbiota to attenuate the tumor burden in ApcMin/+ mice Journal article
Li, Xiaoyan, Khan, Imran, Huang, Guoxin, Lu, Yiyan, Wang, Liping, Liu, Yuanyuan, Lu, Linlin, Hsiao, W. L.Wendy, Liu, Zhongqiu. Kaempferol acts on bile acid signaling and gut microbiota to attenuate the tumor burden in ApcMin/+ mice[J]. European Journal of Pharmacology, 2022, 918.
Authors:  Li, Xiaoyan;  Khan, Imran;  Huang, Guoxin;  Lu, Yiyan;  Wang, Liping; et al.
Favorite | TC[WOS]:27 TC[Scopus]:27  IF:4.2/4.3 | Submit date：2022/09/21
Bile Acid (Ba)  Colorectal Cancer (Crc)  Farnesoid x Receptor (Fxr)  Gut Microbiota (Gm)  Kaempferol  
Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism Journal article
Wang, Songsong, Sheng, Feiya, Zou, Liang, Xiao, Jianbo, Li, Peng. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism[J]. Journal of Advanced Research, 2021, 34, 109-122.
Authors:  Wang, Songsong;  Sheng, Feiya;  Zou, Liang;  Xiao, Jianbo;  Li, Peng
Favorite | TC[WOS]:68 TC[Scopus]:70  IF:11.4/11.0 | Submit date：2022/01/14
Bile Acid Metabolism  Cholesterol Metabolism  Hyperoside  Label-free Proteomics  Nafld  Targeted Metabolomics  
Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors Journal article
Chen X., Yang D., Shen W., Dong H.F., Wang J.M., Oppenheim J.J., Howard O.M.Z.. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors[J]. Inflammation Research, 2000, 49(12), 744-755.
Authors:  Chen X.;  Yang D.;  Shen W.;  Dong H.F.;  Wang J.M.; et al.
Favorite | TC[WOS]:52 TC[Scopus]:52 | Submit date：2018/11/06
Bile Acids  Chemotaxis  Chenodeoxycholic Acid  Formyl Peptide Receptor  Formyl Peptide Receptor Like 1. Calcium Flux